Posted by Michael Wonder on 30 Nov 2021
Merck’s Keytruda (pembrolizumab) approved in Japan in combination with chemotherapy for first-line treatment of patients with radically unresectable, advanced or recurrent oesophageal carcinoma
30 November 2021 - Keytruda is now approved for 16 indications in Japan.
Merck today announced that Keytruda has been approved by the Japan Pharmaceuticals and Medical Devices Agency for the first-line treatment of patients with radically unresectable, advanced or recurrent oesophageal carcinoma in combination with chemotherapy (5-fluorouracil plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.
